Quizartinib latest market price reference

Quizartinib (Quizartinib) is an innovative oral small molecule targeted drug, a second-generation FLT3 inhibitor, mainly used to treat FLT3-ITD mutation-positive acute myeloid leukemia (AML) . This mutation is often associated with clinical features such as rapid disease progression, high recurrence rate, and poor prognosis. Therefore, the emergence of quizartinib provides a new treatment option for such high-risk patients. Its core advantage lies in precisely inhibiting the FLT3 signaling pathway, thereby delaying the spread of leukemia cells and improving the survival time of patients by inhibiting the abnormal proliferation signals of cancer cells.

Another major advantage of quizartinib is that it can be administered orally, which simplifies the treatment process and improves patient compliance. Compared with traditional intravenous chemotherapy regimens, oral drugs have obvious advantages in clinical operation, management and quality of life.

In terms of market, the original drug of Quizartinib is currently on the market in the United States, Europe and Japan. It has not yet been approved for listing in China, so the price in China is not yet clear. In overseas markets, the common specifications of the European version of the original drug Quizartinib include 17.7 mg × 28 tablets and 26.5 mg × 56 tablets, with each box selling for approximately RMB 80,000 to RMB 100,000 (the specific price will fluctuate slightly due to regional taxes and exchange rate changes). This price range is at the high end of targeted anti-cancer drugs.

It is worth noting that some overseas pharmaceutical companies have launched generic versions of Quizartinib, such as the version produced by Lucius Pharmaceutical Factory in Laos. Each box of 14 tablets is sold for about RMB 1,000 (may fluctuate due to exchange rates). The emergence of generic drugs has reduced the financial burden on patients, allowing more patients to obtain treatment through cross-border medical channels. Despite this, patients should still purchase and use them carefully under the guidance of doctors to ensure that the source of the medicine is safe and reliable.

Reference materials:https://go.drugbank.com/drugs/DB12874